Research Article
Thin-Shelled PEGylated Perfluorooctyl Bromide Nanocapsules for Tumor-Targeted Ultrasound Contrast Agent
Table 1
Characteristics of PFOB nanocapsules from different formulations (DLS measurement,
per sample).
| NC | Mixing ratio | Total polymer mass (mg) | dH (nm) | PDI | ζ (mV) | PLGA (%) | PLGA-PEG (%) |
| NC10% | 90 | 10 | 100 | 102.5 ± 0.4 | 0.249 ± 0.02 | −46.2 ± 1.7 | NC20% | 80 | 20 | 100 | 130.0 ± 2.3 | 0.377 ± 0.01 | −42.2 ± 2.9 | NC40% | 60 | 40 | 100 | 113.9 ± 4.2 | 0.306 ± 0.01 | −44.7 ± 2.2 | NC60% | 40 | 60 | 100 | 134.7 ± 1.6 | 0.348 ± 0.02 | −47.0 ± 1.8 | NC80% | 20 | 80 | 100 | 164.2 ± 4.9 | 0.426 ± 0.05 | −42.5 ± 3.6 | NCm20 | 60 | 40 | 20 | 95.6 ± 7.7 | 0.394 ± 0.01 | −30.1 ± 2.3 | NCm40 | 60 | 40 | 40 | 87.0 ± 2.1 | 0.266 ± 0.03 | −29.8 ± 2.4 | NCm100 | 60 | 40 | 100 | 156.6 ± 5.7 | 0.385 ± 0.03 | −27.7 ± 1.3 | Nonlabeled NCm100 | 60 | 40 | 100 | 120.1 ± 2.6 | 0.229 ± 0.02 | −61.4 ± 0.9 | Nonlabeled NCm100 | | | | 101.8 ± 0.3 | 0.157 ± 0.01 | −39.3 ± 0.6 | Cetuximab-labeled NCm100 | 60 | 40 | 100 | 234.1 ± 2.3 | 0.328 ± 0.03 | −50.0 ± 1.2 | Cetuximab-labeled NCm100 | | | | 159.2 ± 1.8 | 0.183 ± 0.02 | −41.0 ± 2.6 |
|
|
Before and after being prepared for in vivo studies, by filtration and short sonication. |